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utcomes Research in Cardiovascular Imaging
eport of a Workshop Sponsored by the National Heart, Lung,
nd Blood Institute
amela S. Douglas, MD,* Allen Taylor, MD,† Diane Bild, MD,‡ Robert Bonow, MD,
hilip Greenland, MD, Michael Lauer, MD,§ Frank Peacock, MD,¶ James Udelson, MD#
urham, North Carolina; Washington, DC; Bethesda, Maryland; Chicago, Illinois;
leveland, Ohio; and Boston, Massachusetts
n July of 2008, the National Heart, Lung, and Blood Institute convened experts in noninvasive
ardiovascular imaging, outcomes research, statistics, and clinical trials to develop recommendations
or future randomized controlled trials of the use of imaging in: 1) screening the asymptomatic patient
or coronary artery disease; 2) assessment of patients with stable angina; 3) identiﬁcation of acute
oronary syndromes in the emergency room; and 4) assessment of heart failure patients with chronic
oronary artery disease with reduced left ventricular ejection fraction. This study highlights several
ossible trial designs for each clinical situation.e
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Mardiovascular imaging is a source of
innovation and controversy for the
health care community. Cardiolo-
gists and radiologists are now capa-
le of obtaining high quality images that
escribe myocardial function and perfusion,
efine risk of major clinical events, and show
oronary anatomy without need for invasive
nstrumentation (1). At the same time, there
s concern that the rapid dissemination of
ardiovascular imaging is a prime example of
costly technology that is enthusiastically
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edical Center, Durham, North Carolina; †Department of Med-
cine, Cardiovascular Research Institute, Washington Hospital
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ung, and Blood Institute, National Institutes of Health, Bethesda,
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eckman Coulter, Biosite, Heartscape, Inovise, Inverness, Ortho
M
Dmbraced without appropriate supporting
cientific evidence (2,3).
During the past 5 years, medical imaging has
rown substantially, with Medicare Part B
osts alone increasing from $6.89 billion in
000 to $14.11 billion in 2005 (105%) of which
n estimated one-third is cardiovascular (3,4).
n addition, there is inconsistent use, with
ome areas of the country having utilization
ates 10 times those of others (5). There is no
lear explanation for the rapid growth; it can-
ot be ascribed entirely to aging of the popu-
linical Diagnostics, and The Medicines Company. He has re-
eived research grants from Abbott, BAS, Biosite, Brahms,
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ditor, JACC: Cardiovascular Imaging; Christopher Kramer, MD,
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D, Associate Editor, JACC: Cardiovascular Imaging.anuscript received October 23, 2008; revised manuscript received
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898ation, changing disease rates, or im-
roved outcomes (3,4). The “value” of
maging in terms of improved health
utcomes or reduced cardiovascular
vents remains subjective, with limited
vidence, often generated with flawed
esearch methodology (6,7). There are
lso concerns that imaging can cause
arm (8,9), that there are few rigorous
egulatory controls, and that utilization
s at least in part driven by self-referral
10) and, in some cases, even direct-to-
onsumer advertising (11).
A commonly cited model for efficacy
n imaging describes 6 hierarchical tiers
f evidence: 1) technical efficacy; 2)
iagnostic accuracy; 3) diagnostic
hinking; 4) therapeutic efficacy; 5) pa-
ient outcome; and 6) societal efficacy
12–14). A recently convened Ameri-
an College of Cardiology–Duke Uni-
ersity think tank on imaging quality in
ardiovascular medicine (15), noted
hat imaging research has primarily fo-
used on diagnostic and prognostic ac-
uracy, with little work directed at de-
ermining the direct impact of imaging
n patient outcomes. As a result,
mong 745 recommendations for car-
iovascular imaging in American Col-
ege of Cardiology and American Heart
ssociation guidelines, only 1% are
ased on Level of Evidence: A (16). In
ontrast, in cancer medicine, random-
zed trials have been completed or are
nder way for assessing the ability of
maging technologies to prevent major
linical events due to breast (17) or lung
ancer (18).
rial Design Considerations
ethodology. Though it may seem log-
cal that diagnosing disease with “better”
maging tests will yield better outcomes,
here are reasons why this may not be so.
or example, some disease detected by
ensitive technologies in fact reflects sub-
linical disease that if left alone would
ever become clinically manifest (19).
his was discovered during large-scale
tudies of mass screening for neuroblas-
oma in children (20). Another unin- aended consequence of advanced imaging
ay be the detection of “nontarget” find-
ngs, such as noncalcified lung nodules,
hat may not have clinical relevance but
equire additional testing and/or proce-
ures. Therefore, a number of scientists
ave argued that a preferred way to de-
nitively determine whether or not any
ew diagnostic test improves outcomes is
hrough properly designed randomized
rials using clinical events as outcomes
21). However, there are a number of
ajor methodological difficulties in de-
igning and implementing randomized
rials in which imaging tests themselves
re the target of randomization (6). Ef-
ects, by definition, have to be indirect as
ests do not directly affect clinical status.
nstead we must presume that they lead
linicians and patients to modify behav-
or, which hopefully will lead to fewer
linical events.
Several issues represent important
onsiderations when planning trials to de-
ermine if imaging can affect outcomes.
omparison group. The initial consider-
tion is whether one is testing a strategy
f performing an imaging test versus not
erforming any imaging, or whether a
omparison is desired between distinct
maging modalities. As an example of the
atter design, 103 patients with chronic
oronary artery disease (CAD) and left
entricular (LV) dysfunction being con-
idered for revascularization (22) were
andomized to either single-photon emis-
ion computed tomography (SPECT),
yocardial perfusion imaging (MPI) or
ositron emission tomography (PET) for
etermination of viability. The imaging
nformation was provided to clinicians
or decision making blinded with regard
o the imaging modality (with polar maps
howing areas of ischemia, infarction,
nd the like) and patients were followed
or 2- to 3-year outcomes. There was no
ifference in event-free survival between
he 2 groups, suggesting that the use of
ither imaging modality to inform revas-
ularization decisions results in similar
utcomes. An ongoing study that repre-
ents the “imaging versus no imaging”
pproach is the WOMEN (What is the tptimal Method for Ischemia Evalua-
ion in WomeN?) study, in which
omen with suspected CAD are ran-
omized to an initial evaluation strategy
f SPECT MPI versus an initial exercise
lectrocardiography (ECG) testing strat-
gy, with the end point of 2-year negative
redictive value for outcome events (23).
hese studies demonstrate that it is fea-
ible to subject imaging modalities to the
ame rigorous comparisons that are stan-
ard for therapeutics.
nd points. An area of substantial un-
ertainty in the evaluation of imaging
utcomes is the appropriate end points
or use in trials. Ideally, end points
ould involve important natural history
utcomes such as death, cardiac death
r composites of cardiac death, and
onfatal cardiovascular events includ-
ng myocardial infarction (MI). How-
ver, the many decisions made “down-
tream” from the imaging results have a
ighly significant effect on outcomes,
uch that the imaging results them-
elves are only 1 of many influences on
utcomes, and thus challenging to iso-
ate. This has led to considerations of
ther end points occurring over a
horter time horizon, including such
etrics as cost-to-diagnosis, cost-to-
redict event, cost-to-prevent nonfatal
vents, and behavior change with risk
actor modification.
fﬁcacy versus effectiveness. Efficacy re-
ers to the performance characteristics
f a test under ideal conditions per-
ormed and interpreted by experts. Ef-
ectiveness refers to test performance
nder “real-life” conditions (24). An
fficacious test does not necessarily
ranslate into an effective test, and ide-
lly imaging modalities would be sub-
ect to both types of analysis. Stowers et
l. (25) reported SPECT imaging effi-
acy in a small study of 46 emergency
epartment (ED) patients randomized
o resting SPECT perfusion imaging or
onventional clinical strategy. Length
f stay and costs were lower in the
maging strategy arm. Effectiveness of
est perfusion imaging was studied in
he ERASE Chest Pain (Emergency
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899oom Assessment of Sestamibi for the
valuation of Chest Pain) trial, in
hich over 2,500 patients were ran-
omized to an initial ED evaluation
trategy of resting SPECT perfusion
maging, in addition to standard test-
ng, or to a nonimaging standard eval-
ation strategy (26). The results dem-
nstrated a reduction in unnecessary
ospital admissions associated with the
maging strategy, suggesting signifi-
ant effectiveness of imaging in this
ituation.
he NHLBI Workshop on Imaging
utcomes Research
he National Heart, Lung, and Blood
nstitute (NHLBI) recently released its
trategic plan for “Shaping the Future
f Research” (27). The importance of
ptimizing diagnostic tests for improv-
ng outcomes is explicitly recognized in
he plan, which states that “research is
eeded to evaluate the extent to which
isk stratification and application of
ersonalized approaches can improve
ffectiveness” (Challenge 3.1.a); that
studies are needed to reduce the inap-
ropriate used of diagnostic tests and
reatments” (Challenge 3.1.c); and that
here is a need to “evaluate the risks,
enefits, and costs of diagnostic tests
nd treatments in representative popu-
ations and settings” (Challenge 3.2.a).
Therefore, on July 21 and July 22,
008, the NHLBI convened experts in
oninvasive cardiovascular imaging, out-
omes research, statistics, and clinical tri-
ls to develop a vision for imaging re-
earch that transcends current reliance on
iagnostic and prognostic end points to a
ew paradigm that focuses on preventive
nd therapeutic value, where value im-
lies an improved clinical outcome
nd/or reduced costs. The panel was
pecifically charged to develop a set of
ecommendations for future analyses and
ossible research funding by NHLBI,
ncluding sample trial designs for 4
re-defined clinical scenarios commonly
ncountered in clinical practice. The 4
cenarios were: 1) screening the asymp-
omatic patient for CAD; 2) assessment sf stable angina; 3) identification of acute
oronary syndromes in the emergency
oom; and 4) assessment of heart failure
atients with chronic CAD with reduced
V ejection fraction. The panel was
sked to identify need, assess feasibility,
nd determine 1 to 2 examples of possible
rial concepts for each scenario. Given
he time limitations, it was recognized
hat these trial overviews would subse-
uently require substantial statistical and
ogistical analysis to become formal, de-
ailed, and actionable trial designs.
creening the Asymptomatic Patient
or CAD
orty years ago, the World Health
rganization (28) first published prin-
iples around which screening pro-
rams can be justified (Table 1), and
any of these principles also apply to
ascular diseases such as CAD. Screen-
ng for abdominal aortic aneurysm is
ow an accepted practice for some pa-
ient groups based on multiple random-
zed controlled trials (29–31). How-
ver, there are also a number of
nknowns that have blunted enthusi-
sm for screening for CAD (32,33).
ontroversy has arisen regarding whether
maging-based risk classification im-
roves selection of patients for treat-
ents and whether outcomes after
creening are improved compared with
raditional risk factor measurements and
isk-factor based treatments (34–36). It
s also unclear from existing data which
atients to screen and how frequently
o perform screening tests.
Cohort studies using coronary cal-
ium measurement have shown the
bility of cardiac computed tomogra-
hy (CT) to identify high-risk asymp-
omatic patients (37). For example, the
ESA (Multi-Ethnic Study of Ath-
rosclerosis) found that coronary cal-
ium (CAC) scores were strongly and
ncrementally (compared with Fram-
ngham risk score [FRS]) associated
ith clinical vascular outcomes in 45-
o 84-year-old subjects (38). Compared
ith CAC scores equal to 0, a CACcore of 300 was associated with a t6-fold higher odds of a major coro-
ary event and a 9-fold higher odds
f any CAD event. Consensus panels
37,39) have concluded that CAC
cores are capable of stratifying pa-
ients into low-, intermediate-, and
igh-risk groupings. Similar predictive
nformation has been published regard-
ng carotid intima-media thickness
easurements (40), although the
ESA trial suggested that CAC is a
tronger predictor of cardiovascular
vents (41). Thus, the use of CAC
ight be the preferred imaging strat-
gy, independent of other consider-
tions such as cost, availability, or
mpact of incidental scan findings, as
single imaging test for screening
urposes.
Despite the demonstrated predictive
alue of CAC and intima-media thick-
ess, enthusiasm among consensus
anels for routine screening is limited
32–34), in part because of the absence
f clinical trials data (34,42,43). The
ossibility that screening can cause
arm in the form of radiation exposure
for CAC) and false reassurance for
eople with high risk factor scores but
ow levels of anatomic disease are often
entioned as reasons for caution in the
doption of screening using imaging
Table 1. World Health Organization Criteria
for Screening
● The condition sought should be an important
health problem for the individual and
community.
● There should be an accepted treatment or
useful intervention for patients with the disease.
● The natural history of the disease should be
adequately understood.
● There should be a latent or early symptomatic
stage.
● There should be a suitable and acceptable
screening test or examination.
● Facilities for diagnosis and treatment should
be available.
● There should be an agreed policy on whom
to treat as patients.
● Treatment started at an early stage should be
of more beneﬁt than treatment started later.
● The cost should be economically balanced in
relation to possible expenditure on medical care
as a whole.
● Case ﬁnding should be a continuing process
and not a once and for all project.ests (34,42,43). However, others have
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900uggested that such data are absent for
any other forms of screening and that
rials of this sort are expensive and
nlikely to be undertaken (35,36). In
he absence of better outcomes data
or use of an imaging strategy for
creening and risk assessment, the
ontroversy between screening advo-
ates and screening detractors cannot
e easily resolved.
ample trial designs. Workshop part-
cipants considered several sample
tudy overviews designed to reach more
efinitive conclusions on the roles of
maging tests for cardiovascular screen-
ng. The first design was an effective-
ess study of asymptomatic men and
omen with intermediate FRS (Fig. 1).
he hypothesis was that CAC testing
ill improve risk stratification resulting
n improved risk factor modification
nd leading to both reduced events and
ower costs. Patients would be random-
zed to receive an invitation for coro-
ary calcium testing versus no invita-
ion for CAC testing. All patients
ould receive an individualized risk
Asymptom
Routine application
calcium scanning w
Men >55, wome
Clinical decisions r
2-5
H
Primary Outcome
Clinical
Intervention
Randomization
Major Inclusion
Hypothesis
Setting
Cardiac CT for
coronary calcium
Figure 1. Sample Trial Design for Imaging in Asy
CT  computed tomography; CV  cardiovascular;
infarction; NIDDM  non insulin-dependent diabetssessment and associated risk interpre- sation including FRS, which would be
rovided to all patients and to their
octors for subsequent treatment with-
ut specific guidance.
Inclusion criteria would be asymp-
omatic individuals with intermediate
RS (6% but 20%) and without
nown CAD, cardiovascular disease,
eripheral artery disease, or renal dis-
ase. The primary outcome would be a
ombined end point consisting of ma-
or clinical events (MI, stroke, congen-
tal heart disease [CHD] death). Major
econdary end points would include
otal health care costs estimated from
ospitalization and doctor and ED vis-
ts, medications, additional tests, qual-
ty of life measurements, behavior
hanges after testing, cardiovascular
rug use, risk factor changes, clinically
ndicated coronary revascularization,
nd other CHD events. The workshop
iscussants proposed a 10% to 20%
eduction in major cardiovascular dis-
ase end points as study design goals.
imilar trials in different populations,
 Intermediate Risk or NIDDM
therosclerosis imaging with coronary
ead to improved net health outcomes.
65 years: Intermediate FRS 6-20%
rding management of CV risk factors
ar rates of MI, Death,
thcare related costs
Standard risk factor
assessment with global
risk calculation
tomatic Patients
 Framingham risk score; MI  myocardial
ellitus.uch as in asymptomatic type 2 diabetes iellitus, commonly considered a CHD
isk equivalent, were also considered.
To address concerns that reliance on
sual physician care may increase the
ikelihood of a negative result, a fully
anaged trial testing the efficacy of a
uideline-based treatment approach
ersus a CAC plus risk factor-based
pproach to individualized therapy of
ardiovascular risk was proposed. The
rial would have similar inclusion and
xclusion criteria and end points as
lready discussed.
ssessment of Stable Angina
valuation of imaging modalities used in
table angina patients. Imaging modal-
ties for use in patients with suspected
r known CAD have generally been
valuated on the basis of accuracy for
he detection of angiographic CAD.
ll of the contemporary imaging mo-
alities—SPECT or PET MPI, stress
chocardiography, cardiac computed to-
ographic angiography (CCTA), and
ardiac magnetic resonance (CMR)—
erform to a clinically acceptable stan-
ard. The next tier of evaluation focus-
ng on prognostic or risk-stratification
tudies has generally demonstrated that
reater abnormalities on SPECT MPI
nd stress echo imaging are associated
ith a higher risk of an incident car-
iovascular event during follow-up
44,45), documenting the “incremental
alue” of the imaging data over previ-
usly available and less expensive to
btain clinical or stress ECG informa-
ion (46–48). Only a very few imaging
andomized controlled studies have
een performed to date of the kind that
ight be considered to constitute
higher level evidence” from the prism
f therapeutic trials (26); however,
hese demonstrate that it is feasible to
ubject imaging modalities to the same
igorous analysis that is standard for
herapeutics.
ample trial designs. In patients without
nown CAD who present with symp-
oms suggestive of CAD and requiringatic
 of a
ill l
n >
ega
 ye
eal
mp
FRSnitial diagnostic/prognostic work-up,
w
d
t
a
e
w
i
d
c
c
g
t
c
h
C
c
h
t
c
C
l
p
t
t
r
v
T
i
i
a
d
g
i
M
r
p
S
t
r
a
t
y
t
D
E
E
f
p
(
f
5
n
r
d
w
m
im
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 7 , 2 0 0 9
J U L Y 2 0 0 9 : 8 9 7 – 9 0 7
Douglas et al.
Outcomes Research in Cardiovascular Imaging
901orkshop participants proposed a trial
esign randomizing patients to an ini-
ial CCTA strategy as compared with
Primary Outcome
Clinical
Intervention
Randomization
Major Inclusion
Hypothesis
Setting Imaging in th
Use of CCTA firs
non-i
Patients without k
suggestive of CAD, req
Clinical decisions reg
CTA or
2 yea
Cost-ef
Anatomic-based testin
with CTA
Figure 2. Sample Trial Design for Imaging in the
CAD  coronary artery disease; CCTA  cardiac co
adverse cardiac events; MPI  myocardial perfusion
Primary Outcome
Clinical
Intervention
Randomization
Major Inclusion
Hypothesis
Setting
Chronic CAD 
Is Routin
Symptom-driven testin
and cost-effective c
Stable CAD, minim
or CABG
Clinical decisions reg
CTA or
2 Year MACE (
Routine functional
imaging test
(Stress SPECT, echo, CM
Figure 3. Sample Trial Design for Imaging in the
CABG  coronary artery bypass graft; CMR  cardi
OMT  optical medical therapy; SPECT  single-ph
toms; other abbreviations as in Figure 2.n initial functional-based testing strat-
gy (Fig. 2). The primary hypotheses
ere that CCTA would result in non-
aluation of Stable Chest Pain
aluation strategy would result in
ior 2 year MACE rates
n CAD, presenting with symptoms
g initial diagnostic/prognostic work-up
ing management (or “layered” testing,
itional stress imaging)
ACE (non-inferiority),
iveness (for superiority)
Functional-based testing:
Exercise testing alone,
or stress MPI/echo
aluation of Patients With Stable Chest Pain
ted tomographic angiography; MACE  major
aging.
 Stable Controlled Symptoms:
ollow-up Imaging Useful?
te after revascularization is non-inferior
ared with routine follow-up imaging
ymptoms on OMT, >2 year post PCI
vascularization with DM
ing management (or “layered” testing,
itional stress imaging)
-inferiority), Cost-effectiveness
No routine testing
(Testing during follow-up
ONLY if clear change in sx)
aluation of Patients With Stable CAD
agnetic resonance; DM  diabetes mellitus;
n emission computed tomography; sx  symp-dnferior 12-month major adverse car-
iovascular event rates and would be
ost-efficient. Secondary end points
ould include rates of invasive an-
iography, effective biological radia-
ion dosages received by patients,
ost-effectiveness in the low likeli-
ood group (hypothesizing that
CTA is more cost-effective), and
ost-effectiveness in the high likeli-
ood group (hypothesizing that func-
ional imaging is more cost-effective).
To address the impact of imaging in
linically stable patients with known
AD and previous myocardial revascu-
arization, workshop participants pro-
osed randomizing clinically stable pa-
ients 2 years after revascularization
o either routine late “screening” for
ecurrent ischemia with stress imaging
ersus symptom-driven testing (Fig. 3).
he hypothesis would be that periodic
maging after revascularization is non-
nferior for major adverse cardiac events
nd cost-effective. For patients ran-
omized to the initial imaging strategy
roup (including any functional imag-
ng test such as SPECT MPI, PET
PI, stress echo, stress CMR), the
esults would be provided to their
hysicians to act on as they see fit.
econdary end points could evaluate
he “yield” of routine late post-
evascularization stress functional im-
ging, the clinical predictors of a posi-
ive test (to potentially enhance the
ield of imaging), and the influence of
ime from revascularization.
iagnosis of Chest Pain in the
mergency Room
mergency department visits in the U.S.
or suspected acute coronary syndrome
atients exceed 10 million individuals
8%), 6.24 million of whom undergo a
airly extensive evaluation. Of the latter,
0% are ultimately determined to have a
oncardiac diagnosis. Unfortunately, cur-
ent technology is often inadequate to
ifferentiate the roughly 85% of patients
ith noncardiac problems from the small
inority with an acute cardiovasculare Ev
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90250), risk scores (e.g., Thrombolysis In
yocardial Infarction [TIMI]) (51), the
hysical exam, chest radiography, and
ven the arrival ECG are nondiagnostic
n 98% of patients (49), and even inter-
retation of the patient’s symptoms is
onstrained by language barriers, recall
uality, and the fact that as many as
ne-third of confirmed MI patients do
ot have chest pain (52).
Given far greater risk associated with
n inappropriate discharge as compared
ith additional diagnostic testing or
ospitalization, test sensitivity is criti-
al. Highly specific testing, though
aluable when positive, may be inade-
uate for safe discharge. Unfortunately,
urrently available biomarker tests have
igh specificity but sensitivity as low as
0% (53), although a “chest pain cen-
er” strategy of serial markers and se-
ective stress testing decreases mortality
nd increases discharges by 37% and
6%, respectively, compared with usual
are (54). Thus, use of this model has
ky rocketed (55–59), despite tremen-
ous cost, average length of hospital-
zation of 17 h, and great inconve-
ience to the patient. Adding the use of
maging technology to usual care may
mprove the system, but prospective
ata are sparse. This limitation has
esulted in vague guideline statements
hat suggest “the potential benefit of
oninvasive coronary angiography is
ikely to be greatest in symptomatic
atients who are at intermediate risk
or coronary artery disease after initial
isk stratification” (60). Future research
s required before general use of ED
maging can be adopted.
ample trial design. In patients present-
ng with symptoms suggestive of acute
oronary syndromes, workshop partici-
ants proposed randomizing patients to
n initial cardiac marker and CCTA
trategy as compared with usual care
Fig. 4). The primary hypothesis would
e that use of a biomarker plus CTA
ischarge strategy is safe and effective
ompared with the present standard of
are. Eligible patients would be those
resenting to the ED with ischemic iymptoms and negative cardiac marker
eterminations. Major exclusion crite-
ia would include cardiac catheteriza-
ion indications (diagnostic ECG
hanges or local positive troponin) and
CTA exclusions (reduced renal func-
ion, known CAD, or significant ar-
hythmia). The primary end point
ould be a combination (major adverse
ardiac events) of death, coronary re-
ascularization intervention, or of heart
ailure. Secondary end points could in-
lude additional clinical outcomes and
esource implications of a marker/CTA
trategy such as ED process time, time
o accurate diagnosis, rates of noncar-
iac diagnoses, and percutaneous coro-
ary interventions (PCI) performed as
consequence of strategy used, dye
oad and complications, radiation expo-
ure, patient satisfaction, and revisits.
ssessment of Heart Failure Patients
ith Chronic CADWith Reduced
jection Fraction
maging plays several important roles
Primary Outcome
Clinical
Intervention
Randomization
Major Inclusion
Hypothesis
A detcepsuSgnitteS
Determine if a m
>10 minutes of isc
No treatment in
30 day and 180 day en
procedures, re
Standard biomarker
assessment with or
without exercise testi
Figure 4. Sample Trial Design for Imaging in the
in the Emergency Department
ACS  acute coronary syndromes; other abbreviatin the current management of patients lith LV systolic dysfunction including:
o assess its severity, to identify those
ith underlying CAD, to determine
he extent and severity of myocardial
schemia, and to identify the magnitude
f dysfunctional but viable myocar-
ium. Only LV ejection fraction has
een studied in prospective randomized
linical trials. Among the many candi-
ate clinical trials in patients with isch-
mic LV dysfunction discussed at this
orkshop, the assessment of myocar-
ial viability and the role of imaging in
schemic mitral regurgitation (MR)
ere selected for consideration, as these
topics have both clinical need and
otential public health impact.
yocardial viability. Numerous studies
ave demonstrated the potential of
ET, SPECT, dobutamine echo, and
ontrast-enhanced CMR to identify vi-
ble myocardium in patients with CAD
nd LV dysfunction, and to predict
ecovery of LV function following per-
utaneous (PCI) or surgical (coronary
rtery bypass graft [CABG]) revascu-
tnemtrapeD ycnegremE eht ni 
er/CTA discharge strategy is safe
d cost-effective
ic symptoms in the prior 24 hours,
ative biomarkers
ention – usual processes of care
oints including survival, cardiovascular
its to the emergency department
Biomarkers plus
 noninvasive coronary
angiography with MDCT
aluation of Patients With Acute Chest Pain
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903urvival and symptomatic status com-
ared with the results of medical ther-
py (62–64). However, these studies
ere all retrospective in nature, often
ith treatment biases based on the
esults of the imaging tests, and the
edically treated patients often did not
eceive aggressive evidence-based med-
cal management.
Even the ongoing NHLBI-funded
TICH (Surgical Treatment for Isch-
mic Heart Failure) trial (65) will leave
nresolved a number of important
uestions as patients were randomized
o revascularization versus aggressive
edical management in patients with
schemic LV dysfunction independent
f imaging results. Further studies are
eeded to address whether an imaging
trategy is useful in actually guiding
anagement decisions in patients with
schemic LV dysfunction.
ample trial design. A possible trial in
his area could test the effectiveness of
outine viability imaging versus nonim-
ging strategy in the management of
atients with symptomatic heart failure
nd multivessel CAD by improving
Primary Outcome
Clinical
Intervention
Randomization
Major Inclusion
Hypothesis
Setting Myocardia
Whether routine v
improves heal
revas
Standard of care w
therapy, percutaneou
Physicians encoura
Total mortality, con
No imaging for viability
Figure 5. Sample Trial Design for Imaging in the
EF  ejection fraction; PET  positron emission tom
as in Figures 2 and 3.utcomes, health status, and/or quality df life and reducing cost. Following
ngiography, patients with 2- or
-vessel CAD and ejection fraction
5% or less would be randomized to
tandard of care therapy (optimal med-
cal therapy or PCI or CABG) without
maging or to a strategy of imaging
ollowed by standard of care (Fig. 5).
deally, a second randomization would
e performed within the imaging arm,
n which patients would be randomized
o one of 4 imaging strategies—PET,
PECT, dobutamine stress echo, or
MR—to determine the relative effect
f each of these tests. Patient care
ould be determined at the discretion
f the treating physician, but physicians
re encouraged to follow the results of
he viability data in patients random-
zed to imaging. The clinical end points
ould include cardiovascular mortality
nd cardiac readmissions for MI, un-
table angina, heart failure, and late
evascularization (excluding planned
CI or CABG based on initial testing).
schemic MR. Patients with ischemic
ardiomyopathy who have MR have a
orse outcome in terms of mortality,
ability in Low EF Patients
≤
lity testing improves outcomes,
tatus/QOL and reduces costs
arization candidates
linical choice of optimal medical 
 surgical coronay revascularization.
 to follow results of viability data.
stive heart failure, late unplanned
ascularization
Imaging for viability
Sub-randomization
SPECT PET CMR DSE
aluation of Patients With Low EF
raphy; QOL  quality of life; other abbreviationsevelopment of heart failure, and hos- citalization than patients without MR
66,67). In this situation, MR develops
econdary to LV dysfunction with di-
ation and displacement of the papillary
uscles, mitral annular dilation and
ethering of the mitral valve leaflets
68). It is unclear whether the resulting
functional” MR is merely a marker of
greater degree of LV dysfunction or
hether it contributes actively to pro-
ression of LV dysfunction. It is also
nclear whether surgery to repair or
eplace the mitral valve leads to a better
utcome (69,70), or whether mild to
oderate MR should be repaired at the
ime of CABG.
ossible trial design. This clinical trial
roposal involves using the infra-
tructure developed by the NHLBI
ardiothoracic Surgery Clinical Re-
earch Network to assess whether
ild to moderate MR should be re-
aired at the time of CABG in pa-
ients with LV dysfunction and could
nclude 3-dimensional echocardiogra-
hy and CMR as part of the prospec-
ive evaluation of patients enrolled in
uch studies. This study would examine
he importance of imaging in identify-
ng which patients with ischemic MR
enefit from mitral valve repair at the
ime of CABG through follow-up echo-
ardiography and CMR at 6 months and
years after surgery (Fig. 6). The study
ould also examine whether and how
maging influences operative decision
aking and outcomes of all-cause mor-
ality and hospital readmissions, includ-
ng whether imaging is helpful in deter-
ining which patients will benefit.
ommon Themes and Concerns
he sample trials considered by the
orkshop share some common
hemes and limitations that, taken
ogether, provide a practical lesson in
ow to think about outcomes research
n imaging. Most trial designs fo-
used on real-world populations and
ere large practical trials intended to
ssess effectiveness and not efficacy.
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904urther testing or therapeutic inter-
ention were left to the patients’ care
eam following randomization. In
ther words, the trials did not specify
ow physicians were to act upon im-
ging results. Some were based on
andomization to the use of imaging
r not and others randomized pa-
ients between imaging strategies.
In general, the sample trial designs
dvocated for use of “hard end points”
uch as death or myocardial infarction
ver at least a 1-year period for pri-
ary end points, rather than relying
n softer outcomes such as clinical
orsening or use of medications.
ost also included a broad variety of
econdary end points such as radia-
ion exposure, assessment of quality
f life, behavior change with risk
actor modification, and economic
nalyses, including such metrics as
ost-to-diagnosis, cost-to-predict
vent, and cost-to-prevent MI. Mo-
ivation for these additional metrics
ncluded the wish to incorporate end
oints that may be less challenging to
Primary Outcome
Clinical
Intervention
Randomization
Major Inclusion
Hypothesis
Setting Imaging in
Imaging MV
and myocardial
Moderate MI in p
<40% u
No treatment in
2 year all cause morta
LV function/v
at 6 m
No imaging for MV
morphology
Figure 6. Sample Trial Design for Imaging of Pa
CHF  congestive heart failure; LV  left ventricula
other abbreviations as in Figures 1 and 2.evelop over a shorter time horizon, ps well as interest in the variables
hemselves. They also reflect the
road range of concerns around im-
ging use.
Many limitations common to the
ample trials are noted. The trial de-
igns were not subject to rigorous eval-
ation of feasibility, in part due to
cknowledged time constraints during
he workshop and lack of analytic ex-
ertise needed to construct detailed
linical protocols, but also by intent so
s not to limit creativity. These chal-
enges also extend beyond the time
onstraints of the workshop format as it
s difficult to properly estimate a sam-
le size in the absence of reliable
ommunity-based data on prevalence
f disease, test performance, end point
ccurrence, effect size, and cross over
ates, among other concerns. It is pos-
ible that initial pilot studies or simu-
ations may be helpful in more detailed
lanning.
Another concern was the duration
f time required to perform such
tudies, especially related to the rapid
chemic Mitral Regurgitation
rphology, mechanism of MR,
bility predicts benefit of MV repair
nts with CAD and ejection fraction
rgoing revascularization
ention – usual processes of care
 and cardiac readmission (CHF or ACS).
mes and mitral valve function 
ths and 2 years postop.
MV imaging with echo,
3-D echo, and CMR
ts With Ischemic MR
R  mitral regurgitation; MV  mitral valve;ace of technologic change, and phether the results would still be
elevant at the time of trial comple-
ion. Finally, all of the sample trials
ould be “large” and “expensive” tri-
ls and that the cost of even 1 such
rial would be quite high, perhaps
ven prohibitive, an especially impor-
ant consideration for NHLBI, as the
onvener of the conference and for
ny future Request For Applications
RFA) that might arise as a result of
he workshop deliberations. Several
lternative solutions in addition to
onventional federal funding were
iscussed including pooling resources
rom the private sector (industry, pay-
rs) with National Institutes of
ealth funds, using only clinically
ndicated (and therefore “covered”)
esting or creating other incentives
or enrollment that might mitigate
his concern. Other strategies pro-
osed to minimize costs included
ombining the emergency room and
table angina trials, with identical end
oints to allow pooling of data, and
dministrative approaches to achieve
conomies of scale such as using a
ingle coordinating center and using
ommon sites and/or data collection
orms for several trials.
Because such practical consider-
tions will be critical going forward,
nd many of these would require addi-
ional thought by multiple stakehold-
rs, an Imaging Outcomes Consortium
as proposed to facilitate further, in-
epth exploration of these strategies.
uch a consortium could also be used to
urther review trial proposals developed
t the workshop, engage key stakehold-
rs, conduct large or smaller trials sub-
tudies or registries, and provide ongo-
ng oversight and support to the
merging outcomes research standard
or imaging.
ummary
iven that Medicare spends over $14
illion per year on Part B imaging
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ardiovascular imaging (4), it is im- Is
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905o understand the scientific basis for
he use of imaging and its contribu-
ion to the nation’s health. Fortu-
ately the research paradigm regard-
ng imaging is changing, with
rowing recognition that there is
oth urgent need and great opportu-
ity in this area (6,15). Future imag-
ng trials must address actual patient
utcomes, instead of sensitivity/2. Gazelle GS, McMahon PM, Siebert U, Bein-
feld MT. Cost-effectiveness analysis in the as-
1
1
1
1
1
1
1
2
2
2
2
2orkshop deliberations, as summa-
ized in this proceedings document,
mply demonstrate both a commit-
ent on the part of multiple stake-
olders to this goal and a shared
elief that this is feasible and timely.
here is much work remaining to be
one, from creating more detailed
nd practical trial designs to deter-
ining sources of funding. It is4. Nallamothu BK, Hayward RA, Bates ER.
Beyond the randomized clinical trial: the
2
2
2
2
2
3
3
3
3ians ordering cardiovascular imaging
ests will have a clear idea of their
alue in improving the health of their
atients.
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